AquaBounty Technologies (NASDAQ:AQB – Get Free Report) and Yarrow Bioscience (NASDAQ:YARW – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, dividends, valuation and earnings.
Analyst Recommendations
This is a summary of recent ratings for AquaBounty Technologies and Yarrow Bioscience, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AquaBounty Technologies | 1 | 0 | 0 | 0 | 1.00 |
| Yarrow Bioscience | 1 | 0 | 2 | 0 | 2.33 |
Yarrow Bioscience has a consensus target price of $58.00, suggesting a potential upside of 122.48%. Given Yarrow Bioscience’s stronger consensus rating and higher possible upside, analysts plainly believe Yarrow Bioscience is more favorable than AquaBounty Technologies.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| AquaBounty Technologies | $2.47 million | 1.84 | -$18.49 million | ($0.82) | -1.07 |
| Yarrow Bioscience | $570,000.00 | 122.12 | -$26.48 million | ($14.64) | -1.78 |
AquaBounty Technologies has higher revenue and earnings than Yarrow Bioscience. Yarrow Bioscience is trading at a lower price-to-earnings ratio than AquaBounty Technologies, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
AquaBounty Technologies has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500. Comparatively, Yarrow Bioscience has a beta of 2.01, meaning that its share price is 101% more volatile than the S&P 500.
Insider & Institutional Ownership
8.9% of AquaBounty Technologies shares are held by institutional investors. Comparatively, 83.8% of Yarrow Bioscience shares are held by institutional investors. 1.0% of AquaBounty Technologies shares are held by company insiders. Comparatively, 3.0% of Yarrow Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares AquaBounty Technologies and Yarrow Bioscience’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| AquaBounty Technologies | N/A | -147.07% | -28.73% |
| Yarrow Bioscience | -4,726.21% | -84.40% | -77.68% |
Summary
Yarrow Bioscience beats AquaBounty Technologies on 8 of the 14 factors compared between the two stocks.
About AquaBounty Technologies
AquaBounty Technologies, Inc., a biotechnology company, operates in the aquaculture industry in the United States and Canada. The company engages in genetic, genomic, and fish health and nutrition research activities. It also operates salmon farms using proprietary technology. In addition, the company offers AquAdvantage Salmon, a genetically engineered Atlantic salmon for human consumption; and sells conventional Atlantic salmon, salmon eggs, fry, and byproducts. The company was formerly known as Aqua Bounty Farms, Inc. and changed its name to AquaBounty Technologies, Inc. in June 2004. AquaBounty Technologies, Inc. was incorporated in 1991 and is headquartered in Harvard, Massachusetts.
About Yarrow Bioscience
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
Receive News & Ratings for AquaBounty Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AquaBounty Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
